- Home
- EPWK vs PHIO Comparison
EPWK vs PHIO Comparison
Compare EPWK & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPWK
- PHIO
- Stock Information
- Founded
- EPWK 2011
- PHIO 2011
- Country
- EPWK China
- PHIO United States
- Employees
- EPWK N/A
- PHIO N/A
- Industry
- EPWK
- PHIO Biotechnology: Pharmaceutical Preparations
- Sector
- EPWK
- PHIO Health Care
- Exchange
- EPWK Nasdaq
- PHIO Nasdaq
- Market Cap
- EPWK 9.5M
- PHIO 10.5M
- IPO Year
- EPWK 2025
- PHIO N/A
- Fundamental
- Price
- EPWK $0.45
- PHIO $2.09
- Analyst Decision
- EPWK
- PHIO Strong Buy
- Analyst Count
- EPWK 0
- PHIO 3
- Target Price
- EPWK N/A
- PHIO $10.67
- AVG Volume (30 Days)
- EPWK 311.2K
- PHIO 2.7M
- Earning Date
- EPWK 05-27-2025
- PHIO 08-14-2025
- Dividend Yield
- EPWK N/A
- PHIO N/A
- EPS Growth
- EPWK N/A
- PHIO N/A
- EPS
- EPWK N/A
- PHIO N/A
- Revenue
- EPWK $20,164,008.00
- PHIO N/A
- Revenue This Year
- EPWK N/A
- PHIO N/A
- Revenue Next Year
- EPWK N/A
- PHIO N/A
- P/E Ratio
- EPWK N/A
- PHIO N/A
- Revenue Growth
- EPWK 10.25
- PHIO N/A
- 52 Week Low
- EPWK $0.41
- PHIO $0.97
- 52 Week High
- EPWK $26.00
- PHIO $9.79
- Technical
- Relative Strength Index (RSI)
- EPWK N/A
- PHIO 39.36
- Support Level
- EPWK N/A
- PHIO $1.91
- Resistance Level
- EPWK N/A
- PHIO $2.29
- Average True Range (ATR)
- EPWK 0.00
- PHIO 0.14
- MACD
- EPWK 0.00
- PHIO -0.02
- Stochastic Oscillator
- EPWK 0.00
- PHIO 32.14
About EPWK EPWK Holdings Ltd. Class A Ordinary Shares
EPWK Holdings Ltd create an innovative and efficient crowdsourcing platform to connect businesses with great talents. It operates online marketplace to enable businesses (buyers) and service providers (sellers) to find each other. The platform users consist of buyers who seek talents for their jobs and sellers who offer different talents and skills. The company derives revenue mainly comes from providing various value-added services for users on both supply and demand sides.
About PHIO Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.